The future of microbiome therapeutics.
Leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases.
A clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies.
Avalanche develops technologies and products for sustained delivery of therapeutic proteins to the eye to treat ophthalmologic disorders.
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases.
Vical is focused on the development of pharmaceutical product candidates based on its patented gene delivery technology.
Trubion Pharmaceuticals is engaged in the research and development of novel medicines to treat human diseases such as rheumatoid arthritis and non-Hodgkin Lymphoma.
Syntonix Pharmaceuticals is developing next generation biopharmaceuticals that enable better treatment options for patients with devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders.
Sirna Therapeutics focuses on developing therapeutics based on RNA interference (RNAi) technology.
Intarcia Therapeutics specializes in developing and systematically generating new uses for clinical-stage drugs.